NIH R01 · 2025
Genetics and Triglycerides: opportunities for new approaches to identify therapies
Lowering TGs to reduce the risk of coronary heart disease (CHD) is an active area of drug development. New drugs under development target TG genes in the lipoprotein lipase (LPL). The status quo is that: (1) we know little about potential beneficial and detrimental effects of long-term inhibition (or activation) of these target TG genes; (2) most TG-lowering drugs in development focus on the LPL pathway--we need to identify new TG targets in other pathways; (3) TG drug development currently targets one gene at a time and neglects agents that affect many genes simultaneously. We propose to fill the knowledge gaps as follows. (1) TG levels are associated with many diseases and TG genes…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.